The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Official Title: A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
Study ID: NCT02210559
Brief Summary: This is a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of FG-3019 administered with gemcitabine and nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
HonorHealth Research Institute, Scottsdale, Arizona, United States
University of California, Los Angeles, Los Angeles, California, United States
Georgetown University - Medstar Health Research Institute, Washington, District of Columbia, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Virginia Mason Medical Center - Benaroya Research Institute, Seattle, Washington, United States
Name: Vincent Picozzi, MD
Affiliation: Virginia Mason Medical Center - Benaroya Research Institute
Role: PRINCIPAL_INVESTIGATOR